MDMałgorzata Dominiak

Małgorzata Dominiak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Małgorzata Dominiak has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care

    by Julia Hofmann, Łukasz ChęTko, Igor Bednarski, Maria Rajczak, Małgorzata Dominiak, Joanna Narbutt, Aleksandra Lesiak

    Objectives: Alopecia areata (AA) is a widespread autoimmune condition causing non-scarring hair loss, significantly affecting the quality of life. Despite its prevalence, data on diagnostic and treatment efficacy and the quality of patient care in Poland remain unstudied. The aim of this study was to assess the current clinical approaches to the diagnosis and management of alopecia areata by dermatologists in Poland and to highlight the challenges encountered by Polish patients. Methods: A cross-sectional study was conducted regarding dermatologists and AA patients in Poland. The data were gathered from distinct proprietary surveys: an original questionnaire for doctors, and DLQI, CDLQI, AAPPO, WPAI+CIQ:AS, and SF-36 questionnaires for patients. Results: The study included 100 dermatologists and 252 patients from Poland. The study revealed that the care provided to patients with alopecia areata is inadequate and lacks a comprehensive approach, despite the negative disease impact on patients’ quality of life. A number of physicians do not follow the diagnostic and treatment guidelines. Despite the registration of next-generation treatments like Janus kinase inhibitors, access to these medications remained limited until recently. Conclusions: Alopecia areata in Poland poses significant diagnostic, therapeutic, and psychosocial challenges. While clinical practice largely aligns with international recommendations, notable gaps remain in the use of validated severity tools, psychosocial assessment, and access to advanced therapies. The recent reimbursement of ritlecitinib represents a breakthrough, bringing Polish care in line with global standards. However, optimal management requires not only pharmacological advances but also interdisciplinary strategies integrating psychological support, patient advocacy, and public education to reduce stigma and improve overall quality of life for affected individuals.

  • Open Access

    Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care

    by Julia Hofmann, Łukasz ChęTko, Igor Bednarski, Maria Rajczak, Małgorzata Dominiak, Joanna Narbutt, Aleksandra Lesiak

    Background/Objectives: Alopecia areata (AA) is a widespread autoimmune condition causing non-scarring hair loss, significantly affecting the quality of life. Despite its prevalence, data on diagnostic and treatment efficacy and the quality of patients’ care in Poland remain unstudied. The aim of this study was to assess the current clinical approaches to the diagnosis and management of alopecia areata by dermatologists in Poland and to highlight the challenges encountered by Polish patients. Methods: A cross-sectional study was conducted regarding dermatologists and AA patients in Po-land. The data were gathered from distinct proprietary surveys: an original questionnaire for doctors, and DLQI, CDLQI, AAPPO, WPAI+CIQ:AS, and SF-36 questionnaires for patients. Results: The study included 100 dermatologists and 252 pa-tients from Poland. The study revealed that the care provided to patients with alopecia areata is inadequate and lacks a comprehensive approach, despite the negative disease impact on patients’ quality of life. A number of physicians do not follow the diagnostic and treatment guidelines. Despite the registration of next-generation treatments like Janus kinase inhibitors, access to these medications remained limited until recently. Conclusions: Alopecia areata in Poland poses significant diagnostic, therapeutic, and psychosocial challenges. While clinical practice largely aligns with international recommendations, notable gaps remain in the use of validated severity tools, psychosocial assessment, and access to advanced therapies. The recent reimbursement of ritlecitinib represents a breakthrough, bringing Polish care in line with global stand-ards. However, optimal management requires not only pharmacological advances but also interdisciplinary strategies integrating psychological support, patient advocacy, and public education to reduce stigma and improve overall quality of life for affected individuals.

  • Open Access

    Retrospective Evaluation of the Impact of the COVID-19 Pandemic on the Incidence of Alopecia Areata in a Single Dermatological Department

    by Łukasz ChęTko, Julia Hofmann, Karolina Brzychcy, Marta Matych, Dorota Sobolewska-Sztychny, Marcin Noweta, Bartosz Zakrzewski, Małgorzata Dominiak, Joanna Narbutt, Aleksandra Lesiak

    Background: Alopecia areata (AA) is an autoimmune disease characterized by diverse patterns of non-scarring hair loss. Due to its susceptibility to immune dysregulation and psychological stress, there is growing speculation regarding the potential role of SARS-CoV-2 infection and the COVID-19 pandemic in its development, recurrence, or exacerbation. This retrospective study aimed to evaluate patients affected by AA from a single dermatological center, specifically focusing on the impact of the COVID-19 pandemic on hospitalization rates. Methods: Data comprising demographic characteristics, disease subtype, number, and duration of hospitalizations were digitized and statistically analyzed. The five-year period prior to the pandemic (2015–2019) was compared with the subsequent four years (2020–2023) to assess any changes. Results: The study involved 428 individuals (256 children and 172 adults), with a slight predominance of women (68.2%). The median ages in adults and children were 39.13 years and 8.66 years, respectively. Following the pandemic, there was a 13.81% decrease in the mean age among adult males. Hospitalizations surged by 207.62% after the pandemic, increasing from 223 to 686 admissions. Additionally, the diagnosis of alopecia areata totalis increased significantly by 55.6%. The residential distribution of pediatric patients also shifted notably, with 72.16% residing in urban areas and 27.84% in rural areas between 2020 and 2023. Conclusions: The significant increase in hospitalization rates and the diversity of disease subtypes observed in this study may suggest a potential correlation between COVID-19 and the development or altered course of alopecia areata. A deeper understanding of this association could enhance treatment outcomes in dermatology, ultimately improving patient care.